A little more than a year after Hikma Pharmaceuticals accused Amarin of “deliberately and meticulously” hamstringing supplies of the main ingredient in its only marketed drug, Vascepa, to thwart potential generic competition, Teva Pharmaceuticals has levied a similar challenge.
Enforcement Report - Week of March 27, 2024
Hikma`s Generic Sodium Acetate Receives Approval in the U.S.
COLUMBUS, Ohio, Feb. 21, 2024 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today welcomed Dr. Rahul Gupta, Director of the White House Office of National Drug Control Policy (ONDCP), to its Columbus, Ohio manufacturing facility for a visit and important dialogue on the US opioid overdose epidemic and Hikma's and ONDCP's shared goal of expanding the availability and awareness of life-saving naloxone.
Hikma`s Generic Levetiracetam Receives Approval in the U.S.
Hikma`s Generic Hydromorphone Hydrochloride Receives Approval in the U.S.
LONDON, Feb. 5, 2024 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the launch of COMBOGESIC® IV (acetaminophen and ibuprofen) injection in the US.
Hikma to pay $115M in cash, $35M in donations to settle opioid claims
Guardant Health and Hikma Partner to Offer Cancer Screening Tests
LONDON, Oct. 3, 2023 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that on the two-year anniversary of its launch, it has now donated more than 375,000 doses of KLOXXADO® (naloxone HCl) nasal spray 8mg in the US – an important milestone in its ongoing work to help combat the opioid overdose epidemic.